T. Rowe Price Associates Increases Stake in Kestra Medical Technologies to 10.2%

On April 8, 2026, T. Rowe Price Associates, Inc. filed an amended Schedule 13G (Amendment No. 1) regarding its holdings in Kestra Medical Technologies (KMTS). The filing indicates that as of March 31, 2026, the investment adviser increased its position to 5,968,664 shares of common stock, representing 10.2% of the company. This is a significant increase from the previously reported 4,369,429 shares, which represented a 7.5% ownership stake. The filing states that T. Rowe Price has sole dispositive power over all 5,968,664 shares and sole voting power over 5,966,639 shares. The securities were acquired in the ordinary course of business and are not held for the purpose of changing or influencing the control of the issuer. The total value of the holdings is estimated at approximately $116.33 million based on the reported data. This filing confirms T. Rowe Price's status as a major institutional shareholder in Kestra Medical Technologies.